Phase 4 N=81 Artificial Tears, Tear Lipids and Tear Film Dynamics
Dry Eye
Primary: Tear Lipid Layer Thickness — 0.72; -7.58; 2.06; 1.41 nm
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=84 Dry Eye Disease Study With Brimonidine
Dry Eye
Primary: Tolerance of Test Substance Visual Analogue Scale (VAS) Score — 82.1; 87.0; 95.0; 91.1 score on a scale
N/A N=161 Study of Safety and Performance of a Novel Ocular Lubricant in Subjects With Dry Eye Disease
Dry Eye Disease
Primary: Change From Baseline in Impact of Dry Eye on Everyday Life - Symptom Bother (IDEEL-SB) Questionnaire Score at Day 30 — -16.95 score on a scale — p=<.0001
Phase 2 N=305 Study to Evaluate the Safety and Efficacy of SDP-4 in Subjects With Dry Eye Disease (DED)
Dry Eye
Primary: Symptom Assessment in Dry Eye (SANDE) Questionnaire — -25.66; -25.14; -29.95; -24.81 units on a scale
Phase 2 N=153 Study to Evaluate the Efficacy of SDP-4 in Subjects With Dry Eye Disease (DED) (SDP-4-CS202)
Dry Eye
Primary: Symptom Assessment in Dry Eye (SANDE) Questionnaire — 58.95; 57.21; -18.80; -16.60 units on a scale
Phase 3 N=80 A Study to Investigate the Effect of 0.003% AR-15512 on Subjects With Dry Eye Disease
Dry Eye Disease
Primary: Least Squares Mean Percentage Change From Baseline in Goblet Cell Density at Day 90 for 0.003% AR-15512 — 94.61 percent change — p=0.1765
Phase 2 N=76 A Multicenter Study Evaluating AZR-MD-001 in Patients With Meibomian Gland Dysfunction and Evaporative Dry Eye Disease (DED)
Meibomian Gland Dysfunction · Dry Eye
Primary: Meibomian Glands Yielding Liquid Secretion (MGYLS) — -0.7; 3.41; 3.07; 1.88 Number of Open Glands
Phase 3 N=252 Study of Brimonidine Tartrate Nanoemulsion Eye Drop Solution in the Treatment of Dry Eye Disease (DED)
Dry Eye
Primary: Change From Baseline to 4 Weeks (Day 28) in Symptom Assessment in Dry Eye (SANDE) Questionnaire Score — 73.0; 72.7; 56.6; 57.2 Score on a scale — p=0.739
Phase 2 N=201 Study of SY-201 Ophthalmic Solution in Subjects With Dry Eye Disease
Dry Eye Disease
Primary: Change From Baseline in Total Corneal Fluorescein Staining (tCFS) at Day 60 — -2.04; -1.65; -2.15; -1.54 tCFS score on a scale of 0 - 20
Phase 3 N=40 A Study to Assess Symptom Relief and Product Tolerability of ABBV-444 Drops in Adult Participants
Dry Eye Syndrome
Primary: Change From Baseline to Day 30 in Ocular Surface Disease Index (OSDI) Score — -6.8 score on a scale
Phase 2 N=336 Perfluorohexyloctane (NOV03) for the Treatment of Signs and Symptoms of Dry Eye Disease (DED)
Dry Eye Disease (DED)
Primary: Corneal Fluorescein Staining (CFS) Total (National Eye Institute (NEI) Grading) — -1.78; -2.11; -0.93 score on a scale
Phase 2 N=172 To Assess the Efficacy and Safety of OTX-DED for the Short-term Treatment of Signs and Symptoms of Dry Eye Disease
Dry Eye
Primary: Photographic Assessment of Bulbar Conjunctival Hyperemia Change in Score From Baseline (CFB) at 15 Days (Evaluated Via Central Reading Center). — -0.51; -0.43; -0.21…
Phase 3 N=81 A Study Designed to Evaluate Tear Production
Dry Eye Disease
Primary: Mean Change From Baseline in Tear Meniscus Height (TMH) at Minute 3 - Stage 1 — 519.65 micrometers — p=<0.0001
Phase 3 N=328 CyclASol for the Treatment of Signs and Symptoms of Dry Eye Disease (DED)
Dry Eye Disease
Primary: Change From Baseline in Total Corneal Fluorescein Staining at Day 29 — -2.9; -2.2 score on a scale
Phase 2 N=102 A Study to Evaluate AXR-159 Ophthalmic Solution in Patients With Dry Eye Disease
Dry Eye
Primary: Inferior Corneal Staining Score — -0.08; -0.03 units on a scale
Phase 3 N=465 Study Evaluating the Safety and Efficacy of AR-15512
Dry Eye Disease
Primary: Percentage of Subjects Who Achieved Equal to or Greater Than 10 Millimeter Increase From Pre-drop at Baseline to Post-drop on Day 14 in Study Eye Unanesthetized Schirmer…
Phase 2 N=85 Phase II Study of SHJ002 Sterile Ophthalmic Solution Compared With Vehicle in Participants With Dry Eye Disease
Dry Eye Disease
Primary: Change From Baseline in Total Corneal Fluorescein Staining (NEI Scale) — -2.4; -1.3 score on a scale
Phase 3 N=467 Study Evaluating the Safety and Efficacy of AR-15512 (COMET-3)
Dry Eye Disease
Primary: Percentage of Subjects Who Achieved Equal to or Greater Than 10 Millimeter Increase From Pre-drop at Baseline to Post-drop on Day 14 in Study Eye Unanesthetized Schirmer…
Phase 3 N=535 Dry Eye Assessment and Management Study
Dry Eye
Primary: Mean of Change From Baseline in Ocular Surface Disease Index (OSDI) Score at 6 and 12 Months — -13.9; -12.5 units on a scale — p=0.40
Phase 3 N=55 A Study to Evaluate 0.003% AR-15512 Safety and Drop Attributes
Dry Eye Disease
Primary: Percentage of Subjects With Ocular Treatment-Emergent Adverse Events Attributed to Study Intervention — 0; 3.6 percentage of subjects
Phase 3 N=400 Efficacy and Safety of a New Artificial Tear Formulation Compared With Systane Ultra Multidose in Participants With Dry Eye Disease
Dry Eye Disease (DED)
Primary: Change From Baseline in Total Staining Score at Day 90 in the Study Eye — -4.5; -3.4 score on a scale — p=0.0475
N/A N=10 Controlled Adverse Environment: A Pilot Study to Evaluate Tear Film Stability and Tear Evaporation
Environmental Exposure
Primary: Tear Evaporation Rate — 39.0; 44.8; 30.6; 26.7 Watt/meter^2
N/A N=15 Non-invasive Tear Film Dynamic Measurements in Normal, MGD and ADDE Subjects After Saline Instillation
Aqueous Deficient Dry Eye · Meibomium Gland Dysfunction
Primary: Visual Quality — 0.3; 0.32; 0.19; 0.3 microns
Phase 3 N=901 Safety and Efficacy of KPI-121 in Subjects With DED
Kerato Conjunctivitis Sicca
Primary: Change From Baseline/Visit 2 (Day 1) in Ocular Discomfort Severity at Visit 4 (Day 15) — -13.58; -8.91 score on a scale
Phase 3 N=597 Perfluorohexylcotane (NOV03) for the Treatment of Signs and Symptoms of Dry Eye Disease Associated With Meibomian Gland Dysfunction (Gobi Study)
Dry Eye Disease (DED)
Primary: Change From Baseline (CFB) in Total Corneal Fluorescein Staining (tCFS) at Day 57 — -2.0; -1.0 units on a scale
Phase 3 N=620 Effect of NOV03 on Signs and Symptoms of Dry Eye Disease Associated With Meibomian Gland Dysfunction (Mojave Study)
Dry Eye Disease
Primary: Change From Baseline in Total Corneal Fluorescein Staining Score (NEI Scale) in the Study Eye at Day 57 — -2.3; -1.1 units on a scale
Phase 2 N=48 A Study of the Drugs AGN-242428 and AGN-231868 in Participants With Dry Eye Disease
Dry Eye Disease · Dry Eye Syndrome
Primary: Stage 1: Number of Participants With Adverse Events — 5; 1; 4; 2 Participants
Phase 2 N=38 Safety and Efficacy of an Ophthalmic Solution in Dry Eye Disease
Dry Eye Disease
Primary: Mean Change From Baseline in Average Lissamine Green Staining in the Study Eye — -0.65 score on a scale
Phase 3 N=242 A Safety and Efficacy Study of a New Eye Drop Formulation in Patients With Dry Eye Disease.
Dry Eye Syndromes
Primary: Change From Baseline in the Ocular Surface Disease Index© (OSDI©) Score — 41.12; 39.63; -15.61; -13.16 score on a scale
Phase 2 N=100 Ocular Tolerability of Voclosporin Ophthalmic Solution Versus Restasis® in Subjects With Dry Eye Disease
Dry Eye
Primary: Change From Baseline in Drop Discomfort Post Dose Instillation on Day 1 — 7.9; 3.5 mm — p=0.1491